← Browse by Condition
Medical Condition

hepatoblastoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1
NCT04337177 Phase 1
Recruiting

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Enrollment
20 pts
Location
United States
Sponsor
Valent Technologies, LLC
View Trial →